|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-5-19
|
|
pubmed:abstractText |
The number of hip fractures is expected to double in the next 20 years, with current estimates that Asia will account for 37% of these cases. As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0300-7995
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
929-37
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16709314-Age Factors,
pubmed-meshheading:16709314-Aged,
pubmed-meshheading:16709314-Aged, 80 and over,
pubmed-meshheading:16709314-Asia, Southeastern,
pubmed-meshheading:16709314-Asian Continental Ancestry Group,
pubmed-meshheading:16709314-Bone Density,
pubmed-meshheading:16709314-Bone Density Conservation Agents,
pubmed-meshheading:16709314-Calcitonin,
pubmed-meshheading:16709314-China,
pubmed-meshheading:16709314-Female,
pubmed-meshheading:16709314-Fractures, Bone,
pubmed-meshheading:16709314-Humans,
pubmed-meshheading:16709314-Middle Aged,
pubmed-meshheading:16709314-Osteoporosis, Postmenopausal,
pubmed-meshheading:16709314-Risk Assessment,
pubmed-meshheading:16709314-Risk Factors,
pubmed-meshheading:16709314-Teriparatide,
pubmed-meshheading:16709314-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.
|
|
pubmed:affiliation |
Dept of Medicine, University of Hong Kong, Queen Mary Hospital, China.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
